Medtech industry, lawmakers concerned about FDA's 510(k) proposals
This article was originally published in SRA
Executive Summary
The cumulative effect of preliminary proposals by the US Food and Drug Administration to overhaul its premarket notification, or 510(k), programme for clearing medical devices could adversely affect the agency's ability to effectively carry out "mission-critical" functions, including timely reviews, industry has warned1,2.